Omeros Competitors

Omeros (NASDAQ:OMER) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Omeros and Johnson & Johnson, as provided by MarketBeat.

Omeros currently has a consensus price target of $23.40, indicating a potential upside of 26.01%. Johnson & Johnson has a consensus price target of $183.25, indicating a potential upside of 10.94%. Given Omeros' higher probable upside, research analysts clearly believe Omeros is more favorable than Johnson & Johnson.

Volatility & Risk

Omeros has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Insider & Institutional Ownership

56.6% of Omeros shares are owned by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are owned by institutional investors. 11.3% of Omeros shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Omeros and Johnson & Johnson's revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Omeros and Johnson & Johnson's net margins, return on equity and return on assets.

Summary

Johnson & Johnson beats Omeros on 10 of the 14 factors compared between the two stocks.

Omeros (NASDAQ:OMER) and Pfizer (NYSE:PFE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Omeros and Pfizer, as provided by MarketBeat.

Omeros presently has a consensus target price of $23.40, indicating a potential upside of 26.01%. Pfizer has a consensus target price of $38.5714, indicating a potential downside of 0.18%. Given Omeros' stronger consensus rating and higher probable upside, research analysts plainly believe Omeros is more favorable than Pfizer.

Insider and Institutional Ownership

56.6% of Omeros shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 11.3% of Omeros shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Omeros and Pfizer's top-line revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Omeros has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Omeros and Pfizer's net margins, return on equity and return on assets.

Summary

Pfizer beats Omeros on 8 of the 14 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Omeros (NASDAQ:OMER) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Merck & Co., Inc. and Omeros, as reported by MarketBeat.

Merck & Co., Inc. presently has a consensus price target of $96.2727, indicating a potential upside of 23.49%. Omeros has a consensus price target of $23.40, indicating a potential upside of 26.01%. Given Omeros' higher possible upside, analysts clearly believe Omeros is more favorable than Merck & Co., Inc..

Profitability

This table compares Merck & Co., Inc. and Omeros' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Merck & Co., Inc. and Omeros' top-line revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Merck & Co., Inc. has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Omeros has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

Insider & Institutional Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 56.6% of Omeros shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 11.3% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Merck & Co., Inc. beats Omeros on 10 of the 14 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Omeros (NASDAQ:OMER) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Risk & Volatility

AbbVie has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Omeros has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.

Profitability

This table compares AbbVie and Omeros' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares AbbVie and Omeros' revenue, earnings per share and valuation.

AbbVie has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.5% of AbbVie shares are held by institutional investors. Comparatively, 56.6% of Omeros shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 11.3% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for AbbVie and Omeros, as provided by MarketBeat.com.

AbbVie presently has a consensus price target of $115.75, indicating a potential upside of 5.18%. Omeros has a consensus price target of $23.40, indicating a potential upside of 26.01%. Given Omeros' higher possible upside, analysts plainly believe Omeros is more favorable than AbbVie.

Summary

AbbVie beats Omeros on 10 of the 14 factors compared between the two stocks.

Omeros (NASDAQ:OMER) and Eli Lilly and (NYSE:LLY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and target prices for Omeros and Eli Lilly and, as provided by MarketBeat.com.

Omeros currently has a consensus target price of $23.40, suggesting a potential upside of 26.01%. Eli Lilly and has a consensus target price of $199.1429, suggesting a potential upside of 6.47%. Given Omeros' higher possible upside, equities analysts plainly believe Omeros is more favorable than Eli Lilly and.

Institutional & Insider Ownership

56.6% of Omeros shares are owned by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are owned by institutional investors. 11.3% of Omeros shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Omeros and Eli Lilly and's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Omeros and Eli Lilly and's revenue, earnings per share and valuation.

Eli Lilly and has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Omeros has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

Summary

Eli Lilly and beats Omeros on 10 of the 14 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Omeros (NASDAQ:OMER) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Omeros' revenue, earnings per share and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Bristol-Myers Squibb and Omeros, as provided by MarketBeat.

Bristol-Myers Squibb currently has a consensus target price of $74.60, suggesting a potential upside of 12.48%. Omeros has a consensus target price of $23.40, suggesting a potential upside of 26.01%. Given Omeros' higher possible upside, analysts clearly believe Omeros is more favorable than Bristol-Myers Squibb.

Institutional and Insider Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 56.6% of Omeros shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 11.3% of Omeros shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Bristol-Myers Squibb and Omeros' net margins, return on equity and return on assets.

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Omeros has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.

Summary

Bristol-Myers Squibb beats Omeros on 10 of the 15 factors compared between the two stocks.